Immupharma Share Discussion Threads

[stockriser] 19/11/2018 14:36

NY Boy - Just after the CEO purchased £100k of shares, DEB dropped almost 50% in three days - they did not provide an RNS.

[arab3] 19/11/2018 14:17

well done ny boy.
I know you traded a lot !
you just forgot to tell everyone when you sold especially
when ramping before the super results that were due.
As for the manic board on a daily basis for months, how many
posts were yours ? lol

good luck with your future bets
sold any VRS today ?

[ny boy] 19/11/2018 13:44

No arab I sold for a loss but only about 25% down overall on as I traded quite a lot from the early days in the 40’s before this board became manic on a daily basis for months. Not tempted to buy as I would have thought the Company would have released an rns after the 100%+ rise over a few days but there again, these are AIM stocks.

[arab3] 19/11/2018 13:10

none left up to the 1.40 days ?

[ny boy] 19/11/2018 12:54

I made a phone call to a broker, they had noted the rise but couldn’t find anything behind it, also there were no major buy trades, I think the max was 270k so nothing major. Could be just some investors taking a collective punt for a trade.

I still have some in the ISA from 40p days but not tempted to buy in here, without some supportive news, as if no rns is forthcoming, it could easily deflate over a period of weeks.

One is always suspicious of AIM stocks!

[kop202] 19/11/2018 12:51

Number of trades is phenominal

[ken chung] 19/11/2018 10:23

A fine short.

[glennrcharles] 19/11/2018 10:15

Anyone phoned the company? And???

[glennrcharles] 19/11/2018 10:03

I sold up at big loss.... well actually at about my purchase price...many months ago. Tempted to get back in but really want so.e good news first.....

[ny boy] 19/11/2018 09:54

Strange after 100% gains, nothing from the Company, I guess having reported widening losses and falling revenues in September, they must be quite pleased with the rise, how long can they plod on for before the next fund raise, remember investors were none too pleased with the sudden fund raise @ 144p, shortly before the share price collapse.

Typical AIM stocks, you really need to research the Director’s track records and do plenty of due diligence.

[fillipe] 19/11/2018 09:26

A lot of "Hot Air" and old regurgitated old news currently floating about the web, at IMM.

Even if the share price has been driven up on fakery, it's perhaps now about at the right level, but unlikely to see a further gains without solid, real news, imo.

f

[kop202] 19/11/2018 09:21

No news will put this into reverse in short order

[kop202] 19/11/2018 09:18

2.7m trades alreadyNo sign of it slowing downTraders paradise

[ny boy] 19/11/2018 09:17

We’re not getting the 100’s of daily posters from the good ole days, so something not quite right here?

[adorling] 19/11/2018 09:09

Any share that goes up 100% in less than 10 trading days with no comment from Company and certain names posting that have a reputation then proceed with caution IMO or call the Company? I am sure the traders who bank their profit are delighted but some bought in this morning and are already 17% down!

[ny boy] 19/11/2018 09:01

I think it’s time for Tim Mc & the IMM board to release an rns to stop the speculation, either there is something behind this rise or not?

[coldspring] 19/11/2018 08:59

It's nearly doubled chap, that's the best pump and dump I have ever seen. It was 10p a week ago hence my comment that something other than that is going on.

[adorling] 19/11/2018 08:55

Has the feel of a classic P&D.

[coldspring] 19/11/2018 08:42

Still booming, something real is driving this. Not just a twitter P&D.

[herb clark] 19/11/2018 08:25

Can't sell!

[jayj4u] 19/11/2018 08:19

woww..... is everyone on the SHIP??? we are leaving..... the high tides are coming... next stop is 50 miles or 50p !!!

[kirk 6] 19/11/2018 08:18

Errrrr booooooooom time broken nice profit We're is that cxxt retirement1 who was rubbing in being on a loss LOOL

[hope67] 18/11/2018 21:26

P140/Forigerimod in other indications

ImmuPharma together with Professor Sylviane Muller, Lupuzor's inventor, have presented new evidence supporting Lupuzor'sâR22;¢ Forigerimod / P140 peptide activity in several other major auto-immune disease indications outside of Lupus. In particular, the peptide appears to have general effects against chronic inflammatory indications and pre-clinical evidence supports the molecule's use in: Neuropsychiatric lupus (NPSLE); Gougerot-Sjögren syndrome (GSS); Chronic Inflammatory Demyelinating Polyneuropathy (CIDP); Arthritis; Crohn's Disease and Asthma.

Oncology and Ophthalmology

ImmuPharma's second most advanced pipeline programme, IPP-204106, is a potential treatment for various cancers and acts by modulating angiogenesis and proliferation. The programme involves the development of synthetic peptides, Nucants, which target certain nuclear proteins such as nucleolin and nucleophosmin on the surface of cells, with very high affinity and selectivity. Nucleolin is a protein which controls critical pathways within the cell. The protein is over-expressed at the surface of dividing cells which makes its binding with Nucants very attractive because of its potential selectivity - this is of particular importance in tumour targeting. We are also investigating its use in age-related macular degeneration where it has demonstrated positive preclinical efficacy results, diabetic retinopathy and other ophthalmological indications.

Metabolism and Diabetes

ImmuPharma's subsidiary 'Ureka' has initiated the development of a novel and innovative peptide technology platform through the collaboration with CNRS, gaining access to pioneering research centred on novel peptide drugs at the University of Bordeaux and the Institut Européen de Chimie et Biologie (IECB). Jointly, ImmuPharma and CNRS have filed a new co-owned patent controlling this breakthrough peptide technology. Ureka's current focus is in Diabetes Type II (GLP-1 analogues - once a month administration); Non-Alcoholic Steato-Hepatitis (NASH) and there is also potential in cancer treatment (protein/protein interaction; P53 gene).